IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 7,323,493

Issue Date:

January 29, 2008

Application No.

09/446,601

Patentees:

Bernard Abramovici, Jean-Claude Gautier, Jean-Claude Gromenil, and

Jean-Marie Marrier

Title: SOLID PHARMACEUTICAL COMPOSITION CONTAINING BENZOFURAN

DERIVATIVES

Certificate of Mailing under 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop Hatch-Waxman PTE address below on the date indicated.

Printed Name of Person Signing Certificate

Mail Stop Hatch-Waxman PTE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.795 and 1.740(13)

Dear Madam:

In accordance with the duty of disclosure described in 37 C.F.R. § 1.765 and acknowledged under 37 C.F.R. § 1.740(13), the Applicant wishes to formally inform the Office that two patent term extension applications have been filed concurrently with respect to the regulatory review period for MULTAQ® (dronedarone hydrochloride). Such patent term extension applications are now pending before the Office and pertain to U.S. Patent Nos. 7,323,493 (i.e., the present application) and 5,223,510. It is requested that the Office examine these applications concurrently so that a meaningful election can be made upon the receipt of a Notice of Final Determination and Requirement of Election as to which patent to ultimately extend in accordance with 37 C.F.R. § 1.785.

IVD000994 US PCT

The Commissioner is hereby authorized to charge any additional fees or underpayments, or credit any overpayments, to Deposit Account 18-1982, upon which the undersigned is authorized to draw.

Respectfully submitted,

January 5, 2010

Kelly L. Bender, Reg. No. 52,610 Attorney for Applicants

they sul

sanofi-aventis U.S. Inc. U.S. Patent Operations 1041 Route 202-206 Bridgewater, New Jersey 08807

Telephone (908) 889-8995

Telefax

(908) 231-2626

sanofi-aventis Docket No. IVD000994 US PCT